Matters to be Discussed: The meeting will convene to address matters related to the conduct of Study section business and for the study section to consider safety and occupational health-related grant applications. Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Price Connor, PhD, NIOSH Health Scientist, 1600 Clifton Road, NE., Mailstop E–20, Atlanta, Georgia 30333, Telephone (404) 498–2511,

Fax (404) 498-2571.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: September 3, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9–21991 Filed 9–11–09; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director, National Institutes of Health; Notice of Public Forums

Notice is hereby given of two forums of the working groups of the NIH Scientific Management Review Board: Deliberating Organizational Changes and Effectiveness Working Group and Substance Use, Abuse and Addition Working Group. The forums will serve as the first among a series of sessions for gathering information on the agency's organizational structure and recommendations for enhancing the NIH mission through greater agency flexibility and responsiveness.

The forums will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The input from these meetings will be summarized in a report that will be presented to the Scientific Management Review Board in open session at an upcoming meeting.

Name of Committee: Substance Use, Abuse, and Addiction Working Group of the Scientific Management Review Board.

Date: September 23, 2009.

Open: 8 a.m. to 3 p.m.

Agenda: Presentation and discussion will include an overview of the science of substance use, abuse, and addiction and the public health needs in this area of research.

Place: National Institutes of Health, Building 60, Chapel and Lecture Hall, 9000 Rockville Pike, Bethesda, MD 20892.

Name of Committee: Deliberating Organizational Change and Effectiveness Working Group of the Scientific Management Review Board.

Date: September 24, 2009. Open: 8 a.m. to 3 p.m.

Agenda: Presentations and discussion will include an overview of NIH mission and function from scientific and stakeholder perspectives, including elaboration upon the principles and attributes fundamental to its success.

Place: National Institutes of Health, Building 60, Chapel and Lecture Hall, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Dr. Lyric Jorgenson, PhD, NIH–AAAS Science and Technology Policy Fellow, Office of Science Policy, Office of the Director, NIH, National Institutes of Health, Building 1, Room 218, MSC 0166, 9000 Rockville Pike, Bethesda, MD 20892, smrb@mail.nih.gov, (301) 496–6837.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. The meeting will also be webcast. The draft meeting agenda and other information about the SMRB, including information about access to the webcast, will be available at http://smrb.od.nih.gov.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxis, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Dated: August 28, 2009.

Lynn Hudson,

Acting Director, Office of Biotechnology Activities.

[FR Doc. E9–22000 Filed 9–11–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Advisory Child Health and Human Development Council, September 21, 2009, 8 a.m. to September 21, 2009, 5 p.m., National Institutes of Health, Building 31, 31 Center Drive, Bethesda, MD 20892 which was published in the **Federal** Register on September 1, 2009, 74 FR 54224.

This notice is being amended to provide additional attendee viewing and Videocast access instructions for open session of Council. In order to facilitate public attendance at the open session of Council, reserve seating will be made available to the first five individuals reserving seats in the main meeting room, Conference Room 6. Please Contact Ms. Lisa Kaeser, Program and Public Liaison Office, NICHD, at 301-496-0536 to make your reservation. Additional seating will be available in the meeting overflow rooms, Conference Rooms 7 and 8. Individuals will also be able to view the meeting via NIH Videocast. Please go to the following link for Videocast access instructions at: http://www.nichd.nih.gov/about/ overview/advisory/nachhd/virtualmeeting-200910.cfm. The meeting is partially closed to the public.

Dated: September 3, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–21998 Filed 9–11–09; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2009-N-0667] [FDA 225-09-0010]

Memorandum of Understanding With Duke University

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
Administration (FDA) is providing
notice of a memorandum of
understanding (MOU) between the Food
and Drug Administration and Duke
University. The purpose of this MOU is
to establish a framework for
collaboration between the Parties and
for pursuing specific collaborative
projects. This collaboration between the
Parties shall be known as the Cardiac
Safety Research Consortium.

DATES: The agreement became effective August 4, 2009.

FOR FURTHER INFORMATION CONTACT:

Wendy R. Sanhai, Office of the Commissioner (HZ–1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7867, FAX: 301–827–5891.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c),